Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Cancer Gene Ther. 2023 Jan;30(1):96-107. doi: 10.1038/s41417-022-00528-4. Epub 2022 Sep 9.
The abnormal activation of the nuclear factor-kappa B (NF-κB) signaling pathway is an important precipitating factor for the inception and development of colorectal cancer (CRC), one of the most common tumors worldwide. As a pro-apoptotic transcription factor, monocyte chemotactic protein-induced protein 1 (MCPIP1) has been closely associated with many tumor types. In the present study, the expression of MCPIP1 was firstly discovered reduced in CRC tissues and correlated with poor patient prognosis. The decreased expression was caused by promoter hypermethylation. Overexpressed MCPIP1 was found to inhibit the proliferative and migratory abilities of CRC cells, whereas knockdown of MCPIP1 produced the opposite result. The subsequent investigation demonstrated that MCPIP1 exerted its "anti-cancer" effect by suppression of the NF-κB signaling pathway through negative regulation of K63-linked ubiquitylation of TNF receptor associated factor 6 (TRAF6). Therefore, our results indicate a prognostic marker for CRC and a theoretical basis for MCPIP1 as a treatment.
核因子-κB(NF-κB)信号通路的异常激活是结直肠癌(CRC)发生和发展的重要促成因素,CRC 是全球最常见的肿瘤之一。单核细胞趋化蛋白诱导蛋白 1(MCPIP1)作为一种促凋亡转录因子,与许多肿瘤类型密切相关。在本研究中,首次发现 MCPIP1 在 CRC 组织中表达降低,并与患者预后不良相关。这种表达降低是由启动子过度甲基化引起的。过表达 MCPIP1 被发现抑制 CRC 细胞的增殖和迁移能力,而敲低 MCPIP1 则产生相反的结果。随后的研究表明,MCPIP1 通过负调控肿瘤坏死因子受体相关因子 6(TRAF6)的 K63 连接泛素化来抑制 NF-κB 信号通路,从而发挥其“抗癌”作用。因此,我们的结果表明 MCPIP1 是 CRC 的预后标志物和治疗的理论基础。